Sharon Mates, Director of Seaport Therapeutics SPTX, has filed 0 purchases and 50 sales on the open market. The latest trade was on 04/30.

SM

SM

Sharon Mates

Director

Company

Seaport Therapeutics SPTX

First filing

23/02/22

Trades

134 trades

Buys / sales

0 / 50

12-month net buying

No record

Last trade

04/30

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
IT Intra-Cellular Therapies	Open-market sale10b5-1 plan	24/12/04–24/12/05	24/12/06	102,697 sh4 trades	$84.93avg.	$8,722,102.78	−8.8%
IT Intra-Cellular Therapies	Open-market sale10b5-1 plan	24/08/29–24/08/30	24/08/30	70,000 sh4 trades	$72.70avg.	$5,089,104.03	−6.1%
IT Intra-Cellular Therapies	Open-market sale10b5-1 plan	24/08/26–24/08/28	24/08/28	95,925 sh5 trades	$73.54avg.	$7,053,850.22	−8.2%
IT Intra-Cellular Therapies	Open-market sale10b5-1 plan	24/08/21–24/08/23	24/08/23	121,073 sh7 trades	$75.05avg.	$9,086,735.83	−10.2%
IT Intra-Cellular Therapies	Open-market sale10b5-1 plan	24/03/07–24/03/11	24/03/11	61,277 sh6 trades	$66.07avg.	$4,048,400.14	−5.5%
IT Intra-Cellular Therapies	Open-market sale10b5-1 plan	24/02/26	24/02/27	22,590 sh3 trades	$69.79avg.	$1,576,464.42	−2.1%
IT Intra-Cellular Therapies	Open-market sale10b5-1 plan	24/02/02	24/02/05	33,885 sh2 trades	$67.07avg.	$2,272,693.5	−3.1%
IT Intra-Cellular Therapies	Open-market sale10b5-1 plan	24/01/16–24/01/18	24/01/18	191,362 sh7 trades	$66.27avg.	$12,680,892.16	−15.4%
IT Intra-Cellular Therapies	Open-market sale10b5-1 plan	23/09/18–23/09/19	23/09/19	100,000 sh3 trades	$53.94avg.	$5,394,064.85	−8.7%
IT Intra-Cellular Therapies	Open-market sale	23/03/10–23/03/13	23/03/13	62,335 sh4 trades	$43.76avg.	$2,727,840.89	−5.2%
IT Intra-Cellular Therapies	Open-market sale	23/02/24	23/02/27	22,590 sh	$47.03	$1,062,407.7	−2.0%
IT Intra-Cellular Therapies	Open-market sale	23/02/21	23/02/22	27,848 sh4 trades	$46.83avg.	$1,304,000.3	−2.5%